Cart
sales@molnova.com
Bcl-B inhibitor 1
CAS No. 79220-88-5
Bcl-B inhibitor 1( —— )
Catalog No. M36960 CAS No. 79220-88-5
Bcl-B inhibitor 1 is an antitumor compound that binds to and inactivates pro-apoptotic proteins in the BH3 structural domain.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 29 | In Stock |
|
| 25MG | 48 | In Stock |
|
| 50MG | 63 | In Stock |
|
| 100MG | 100 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBcl-B inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionBcl-B inhibitor 1 is an antitumor compound that binds to and inactivates pro-apoptotic proteins in the BH3 structural domain.
-
DescriptionBcl-B inhibitor 1 is a Bcl-B inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis | BCL
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number79220-88-5
-
Formula Weight309.39
-
Molecular FormulaC17H15N3OS
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS=C1N(C=C(N1)C2=CC=CC=C2)C3=CC=C(NC(C)=O)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Siva Rajesh, et al. Computational designing of novel inhibitors to Bcl-B, an anti-apoptotic protein, using fragment-based drug designing approach. Romanian Biotechnological Letters 18(5):8613-8621.
molnova catalog
related products
-
ACBI1
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4, also degrades the polybromo-associated BAF (PBAF) complex member PBRM1, with DC50s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.
-
Protein kinase inhib...
Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
-
Methylisoindigotin
Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).
